IDEAS home Printed from https://ideas.repec.org/r/eee/respol/v26y1997i4-5p429-446.html
   My bibliography  Save this item

Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Kremena Slavova & Andrea Fosfuri & Julio O. De Castro, 2016. "Learning by Hiring: The Effects of Scientists’ Inbound Mobility on Research Performance in Academia," Organization Science, INFORMS, vol. 27(1), pages 72-89, February.
  2. Fabienne Orsi & Jean-Paul Moatti, 2001. "D'un droit de propriété intellectuelle sur le vivant aux firmes de génomique : vers une marchandisation de la connaissance scientifique sur le génome humain," Économie et Prévision, Programme National Persée, vol. 150(4), pages 123-138.
  3. Lynne G. Zucker & Michael R. Darby, 2014. "Defacto and Deeded Intellectual Property: Knowledge-Driven Co-Evolution of Firm Collaboration Boundaries and IPR Stragtegy," Annals of Economics and Statistics, GENES, issue 115-116, pages 221-251.
  4. McMillan, G. Steven & Narin, Francis & Deeds, David L., 2000. "An analysis of the critical role of public science in innovation: the case of biotechnology," Research Policy, Elsevier, vol. 29(1), pages 1-8, January.
  5. Ion Anghel & Marian Siminica & Mirela Cristea & Mirela Sichigea & Gra?iela Georgiana Noja, 2018. "Intellectual Capital and Financial Performance of Biotech Companies in the Pharmaceutical Industry," The AMFITEATRU ECONOMIC journal, Academy of Economic Studies - Bucharest, Romania, vol. 20(49), pages 631-631, August.
  6. Lynne G. Zucker & Michael R. Darby, 2009. "Star Scientists, Innovation and Regional and National Immigration," Chapters, in: David B. Audretsch & Robert E. Litan & Robert Strom (ed.),Entrepreneurship and Openness, chapter 6, Edward Elgar Publishing.
  7. Konstantinos Grigoriou & Frank T. Rothaermel, 2017. "Organizing for knowledge generation: internal knowledge networks and the contingent effect of external knowledge sourcing," Strategic Management Journal, Wiley Blackwell, vol. 38(2), pages 395-414, February.
  8. Frédéric Corolleur & Vincent Mangematin & A. Torre, 2003. "French Biotech Start-Ups and Biotech Clusters in France. The Importance of Geographic Proximity," Grenoble Ecole de Management (Post-Print) hal-00424183, HAL.
  9. Giovanni Abramo & Ciriaco Andrea D’Angelo & Anastasiia Soldatenkova, 2017. "How long do top scientists maintain their stardom? An analysis by region, gender and discipline: evidence from Italy," Scientometrics, Springer;Akadémiai Kiadó, vol. 110(2), pages 867-877, February.
  10. Michael R. Darby & Lynne G. Zucker, 1999. "Local Academic Science Driving Organizational Change: The Adoption of Biotechnology by Japanese Firms," NBER Working Papers 7248, National Bureau of Economic Research, Inc.
  11. Hyunju Rachel Kim, 2014. "Formulation of a Success Model in Pharmaceutical R&D," SAGE Open, , vol. 4(1), pages 21582440145, March.
  12. Frank T. Rothaermel & Andrew M. Hess, 2007. "Building Dynamic Capabilities: Innovation Driven by Individual-, Firm-, and Network-Level Effects," Organization Science, INFORMS, vol. 18(6), pages 898-921, December.
  13. Kwangsoo Shin & Sang Ji Kim & Gunno Park, 2016. "How does the partner type in R&D alliances impact technological innovation performance? A study on the Korean biotechnology industry," Asia Pacific Journal of Management, Springer, vol. 33(1), pages 141-164, March.
  14. Masao Nakamura & Robert Dalpé, 2003. "Interaction between public research organizations and industry in biotechnology," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 24(2-3), pages 171-185.
  15. Amit Jain, 2016. "Learning by hiring and change to organizational knowledge: Countering obsolescence as organizations age," Strategic Management Journal, Wiley Blackwell, vol. 37(8), pages 1667-1687, August.
  16. repec:aud:audfin:v:20:y:2018:i:49:p:631 is not listed on IDEAS
  17. Marc-Hubert Depret & Abdelillah Hamdouch, 2004. "La gouvernance des jeunes entreprises innovantes:un éclairage analytique à partir du cas des sociétés de biotechnologies," Revue Finance Contrôle Stratégie, revues.org, vol. 7(2), pages 67-94, June.
  18. Gilsing, Victor & Nooteboom, Bart, 2006. "Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology," Research Policy, Elsevier, vol. 35(1), pages 1-23, February.
  19. Sternitzke, Christian, 2010. "Knowledge sources, patent protection, and commercialization of pharmaceutical innovations," Research Policy, Elsevier, vol. 39(6), pages 810-821, July.
  20. Kafouros, Mario & Wang, Chengqi & Piperopoulos, Panagiotis & Zhang, Mingshen, 2015. "Academic collaborations and firm innovation performance in China: The role of region-specific institutions," Research Policy, Elsevier, vol. 44(3), pages 803-817.
  21. Zhifeng Yin & Qiang Zhi, 2017. "Dancing with the academic elite: a promotion or hindrance of research production?," Scientometrics, Springer;Akadémiai Kiadó, vol. 110(1), pages 17-41, January.
  22. Lynne G. Zucker & Michael R. Darby & Yusheng Peng, 1998. "Fundamentals or Population Dynamics and the Geographic Distribution of U.S. Biotechnology Enterprises, 1976-1989," NBER Working Papers 6414, National Bureau of Economic Research, Inc.
  23. Anna Giunta & Filippo M. Pericoli & Eleonora Pierucci, 2016. "University–Industry collaboration in the biopharmaceuticals: the Italian case," The Journal of Technology Transfer, Springer, vol. 41(4), pages 818-840, August.
  24. Marta F. Arroyabe & Katrin Hussinger & John Hagedoorn, 2020. "Hiring New Key Inventors to Improve Firms’ Post-M&A Inventive Output," CREA Discussion Paper Series 20-19, Center for Research in Economic Analysis, University of Luxembourg.
  25. Wry, Tyler & Lounsbury, Michael, 2013. "Contextualizing the categorical imperative: Category linkages, technology focus, and resource acquisition in nanotechnology entrepreneurship," Journal of Business Venturing, Elsevier, vol. 28(1), pages 117-133.
  26. J. P. Eggers & Sarah Kaplan, 2009. "Cognition and Renewal: Comparing CEO and Organizational Effects on Incumbent Adaptation to Technical Change," Organization Science, INFORMS, vol. 20(2), pages 461-477, April.
  27. Kneller, Robert, 2003. "Autarkic drug discovery in Japanese pharmaceutical companies: insights into national differences in industrial innovation," Research Policy, Elsevier, vol. 32(10), pages 1805-1827, December.
  28. Poonam Khanna & Lemaro Thompson & Michael Mcdonald, 2015. "Research On Venture Capital Firms’ ‘Investment Behavior A Review’," Working Papers 0197mgt, College of Business, University of Texas at San Antonio.
  29. Hopkins, Michael M. & Nightingale, Paul, 2006. "Strategic risk management using complementary assets: Organizational capabilities and the commercialization of human genetic testing in the UK," Research Policy, Elsevier, vol. 35(3), pages 355-374, April.
  30. Rebecca R. Kehoe & Daniel Tzabbar, 2015. "Lighting the way or stealing the shine? An examination of the duality in star scientists' effects on firm innovative performance," Strategic Management Journal, Wiley Blackwell, vol. 36(5), pages 709-727, May.
  31. Jaideep Anand & Raffaele Oriani & Roberto S. Vassolo, 2010. "Alliance Activity as a Dynamic Capability in the Face of a Discontinuous Technological Change," Organization Science, INFORMS, vol. 21(6), pages 1213-1232, December.
  32. Williams, David R., 2013. "Human and financial capital as determinants of biopharmaceutical IPO de-listings," Journal of Business Research, Elsevier, vol. 66(12), pages 2612-2618.
IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.